$249.65
5.602.29%
Últ. Act.: Oct 29, 4:00 PM
Biogen (BIIB) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Biogen (BIIB) emitió su última guía sobre octubre 28, 2026 para fiscal year 2026. La compañía estimó unas ganancias por acción en el rango de $15.95 - $16.75, en comparación con una estimación de consenso de EPS de $12.35.
En comparación con la previsión anterior, Biogen mantenido redujo su previsión de BPA desde un rango anterior de $15.85 - $16.85.
Biogen ha emitido 16 actualizaciones de orientación entre el febrero 15, 2023 y el octubre 28, 2026. During this period, the company raised its outlook 6 times and lowered it 4 times, providing investors with insight into management's evolving expectations.
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $1.99 | $2.35 | $2.95 | $1.62 |
| Actual | $2.62 | $3.60 | $3.57 | $1.99 |
| Surprise | +31.7% | +53.2% | +21.0% | +22.8% |
| Revenue | ||||
| Estimate | $2.63B | $2.42B | $2.25B | $2.21B |
| Actual | $2.80B | $2.74B | $2.48B | $2.28B |
| Surprise | +6.79% | +13.0% | +10.2% | +3.29% |
| Metric | Q4 '26E | Q1 '27E | Q2 '27E | Q3 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $3.06 | $3.56 | $4.31 | $4.30 |
| Revenue | ||||
| Consensus | $2.58B | $2.59B | — | — |
| Trimestre Fiscal | Fecha reportada | EPS real | EPS estimado | Sorpresa % |
|---|---|---|---|---|
| Q3 | Oct 28, 2026 | $2.62 | $1.99 | 31.7 % |
| Q2 | Jul 29, 2026 | $3.60 | $2.35 | 53.2 % |
| Q1 | Apr 29, 2026 | $3.57 | $2.95 | 21.0 % |
| Q4 | Feb 6, 2026 | $1.99 | $1.62 | 22.8 % |
| Trimestre Fiscal | Fecha reportada | Ingresos reales | Ingresos estimados | Sorpresa % |
|---|---|---|---|---|
| Q3 | Oct 28, 2026 | $2.80B | $2.63B | 6.79 % |
| Q2 | Jul 29, 2026 | $2.74B | $2.42B | 13.0 % |
| Q1 | Apr 29, 2026 | $2.48B | $2.25B | 10.2 % |
| Q4 | Feb 6, 2026 | $2.28B | $2.21B | 3.29 % |